Jane Street Group LLC Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Jane Street Group LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 52,998 shares of the specialty pharmaceutical company’s stock after selling 848 shares during the period. Jane Street Group LLC’s holdings in Supernus Pharmaceuticals were worth $1,652,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in SUPN. Commonwealth Equity Services LLC grew its stake in Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after purchasing an additional 350 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 398 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock valued at $741,000 after acquiring an additional 600 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Supernus Pharmaceuticals by 2.8% in the 3rd quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock valued at $1,043,000 after acquiring an additional 908 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Trading Up 1.9 %

NASDAQ:SUPN opened at $36.28 on Friday. The stock has a 50 day moving average of $35.83 and a 200-day moving average of $32.45. The firm has a market capitalization of $2.00 billion, a PE ratio of 33.91 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm’s revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.29) EPS. As a group, analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Frank Mottola sold 15,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. This represents a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last quarter. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.